
Adam M. Weidner
Examiner (ID: 2321, Phone: (571)272-3045 , Office: P/1649 )
| Most Active Art Unit | 1649 |
| Art Unit(s) | 1649, 1651, 1675 |
| Total Applications | 776 |
| Issued Applications | 452 |
| Pending Applications | 81 |
| Abandoned Applications | 249 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18619178
[patent_doc_number] => 11752200
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-12
[patent_title] => Methods of treating neurological disorders
[patent_app_type] => utility
[patent_app_number] => 17/153553
[patent_app_country] => US
[patent_app_date] => 2021-01-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 13
[patent_no_of_words] => 24214
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17153553
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/153553 | Methods of treating neurological disorders | Jan 19, 2021 | Issued |
Array
(
[id] => 18308544
[patent_doc_number] => 20230112444
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => COMBINATION THERAPIES OF CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND GAMMA SECRETASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/758913
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27016
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17758913
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/758913 | COMBINATION THERAPIES OF CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND GAMMA SECRETASE INHIBITORS | Jan 14, 2021 | Pending |
Array
(
[id] => 18428734
[patent_doc_number] => 11673944
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-13
[patent_title] => Treatment of tauopathies
[patent_app_type] => utility
[patent_app_number] => 17/148690
[patent_app_country] => US
[patent_app_date] => 2021-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 38508
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17148690
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/148690 | Treatment of tauopathies | Jan 13, 2021 | Issued |
Array
(
[id] => 18590257
[patent_doc_number] => 11739140
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-29
[patent_title] => Antibodies specific for hyperphosphorylated tau and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/144355
[patent_app_country] => US
[patent_app_date] => 2021-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 51
[patent_figures_cnt] => 67
[patent_no_of_words] => 36709
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17144355
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/144355 | Antibodies specific for hyperphosphorylated tau and methods of use thereof | Jan 7, 2021 | Issued |
Array
(
[id] => 18197720
[patent_doc_number] => 20230051239
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-16
[patent_title] => COMPOSITIONS OF HYDROGELS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/790692
[patent_app_country] => US
[patent_app_date] => 2020-12-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19278
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -44
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17790692
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/790692 | COMPOSITIONS OF HYDROGELS AND METHODS OF USE THEREOF | Dec 30, 2020 | Abandoned |
Array
(
[id] => 18604695
[patent_doc_number] => 11746145
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-05
[patent_title] => Tau-binding antibodies
[patent_app_type] => utility
[patent_app_number] => 17/136440
[patent_app_country] => US
[patent_app_date] => 2020-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 26038
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17136440
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/136440 | Tau-binding antibodies | Dec 28, 2020 | Issued |
Array
(
[id] => 16778043
[patent_doc_number] => 20210115121
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-22
[patent_title] => TAU-BINDING ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/136189
[patent_app_country] => US
[patent_app_date] => 2020-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25804
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17136189
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/136189 | Tau-binding antibodies | Dec 28, 2020 | Issued |
Array
(
[id] => 18701369
[patent_doc_number] => 11787868
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-17
[patent_title] => Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/130477
[patent_app_country] => US
[patent_app_date] => 2020-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23023
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17130477
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/130477 | Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use | Dec 21, 2020 | Issued |
Array
(
[id] => 18701369
[patent_doc_number] => 11787868
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-17
[patent_title] => Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/130477
[patent_app_country] => US
[patent_app_date] => 2020-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23023
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17130477
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/130477 | Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use | Dec 21, 2020 | Issued |
Array
(
[id] => 17958637
[patent_doc_number] => 20220339217
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-27
[patent_title] => PROBIOTIC FORMULATIONS FOR LIVER AND ORAL HEALTH AND ENHANCEMENT OF IMMUNITY
[patent_app_type] => utility
[patent_app_number] => 17/788490
[patent_app_country] => US
[patent_app_date] => 2020-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5071
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17788490
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/788490 | PROBIOTIC FORMULATIONS FOR LIVER AND ORAL HEALTH AND ENHANCEMENT OF IMMUNITY | Dec 20, 2020 | Abandoned |
Array
(
[id] => 16915866
[patent_doc_number] => 20210188958
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => B-CELL EPITOPE OF TRICHINELLA SPIRALIS CYSTEINE PROTEASE INHIBITOR, HYBRIDOMA CELL LINE, MONOCLONAL ANTIBODY AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/128110
[patent_app_country] => US
[patent_app_date] => 2020-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6274
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17128110
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/128110 | B-cell epitope of | Dec 18, 2020 | Issued |
Array
(
[id] => 18636208
[patent_doc_number] => 11760793
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-19
[patent_title] => Antibody for skewing sex ratio and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/126677
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 17
[patent_no_of_words] => 8961
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17126677
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/126677 | Antibody for skewing sex ratio and methods of use thereof | Dec 17, 2020 | Issued |
Array
(
[id] => 17213327
[patent_doc_number] => 20210346663
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => METHODS FOR IMPROVING DRUG EFFICACY
[patent_app_type] => utility
[patent_app_number] => 17/125172
[patent_app_country] => US
[patent_app_date] => 2020-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16020
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17125172
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/125172 | METHODS FOR IMPROVING DRUG EFFICACY | Dec 16, 2020 | Abandoned |
Array
(
[id] => 18590260
[patent_doc_number] => 11739143
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-29
[patent_title] => Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
[patent_app_type] => utility
[patent_app_number] => 17/122325
[patent_app_country] => US
[patent_app_date] => 2020-12-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 42
[patent_no_of_words] => 34506
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17122325
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/122325 | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same | Dec 14, 2020 | Issued |
Array
(
[id] => 17185229
[patent_doc_number] => 20210332114
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-28
[patent_title] => ANTI-TAU ANTIBODIES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/110969
[patent_app_country] => US
[patent_app_date] => 2020-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54648
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17110969
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/110969 | Anti-Tau antibodies and methods of use | Dec 2, 2020 | Issued |
Array
(
[id] => 16837910
[patent_doc_number] => 20210145922
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => ANG (1-7) DERVIATIVE OLIGOPEPTIDES FOR THE TREATMENT OF PAIN
[patent_app_type] => utility
[patent_app_number] => 17/109604
[patent_app_country] => US
[patent_app_date] => 2020-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15364
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17109604
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/109604 | ANG (1-7) DERVIATIVE OLIGOPEPTIDES FOR THE TREATMENT OF PAIN | Dec 1, 2020 | Abandoned |
Array
(
[id] => 18108118
[patent_doc_number] => 20230000998
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => BBB-SHUTTLING-VNARS CONJUGATED TO NEUROTROPHIC AGONIST ANTIBODIES TO TREAT NEURODEGENERATIVE DISEASES AND CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 17/778665
[patent_app_country] => US
[patent_app_date] => 2020-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15273
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778665
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/778665 | BBB-SHUTTLING-VNARS CONJUGATED TO NEUROTROPHIC AGONIST ANTIBODIES TO TREAT NEURODEGENERATIVE DISEASES AND CONDITIONS | Nov 19, 2020 | Pending |
Array
(
[id] => 17168669
[patent_doc_number] => 20210322339
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA
[patent_app_type] => utility
[patent_app_number] => 17/100674
[patent_app_country] => US
[patent_app_date] => 2020-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26541
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17100674
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/100674 | COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA | Nov 19, 2020 | Abandoned |
Array
(
[id] => 18075887
[patent_doc_number] => 20220401499
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-22
[patent_title] => NEW USE OF BIFIDOBACTERIUM LACTIS BL-99 IN SUPPRESSION OF INTESTINAL INFLAMMATION
[patent_app_type] => utility
[patent_app_number] => 17/778587
[patent_app_country] => US
[patent_app_date] => 2020-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5071
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778587
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/778587 | NEW USE OF BIFIDOBACTERIUM LACTIS BL-99 IN SUPPRESSION OF INTESTINAL INFLAMMATION | Nov 18, 2020 | Pending |
Array
(
[id] => 16671361
[patent_doc_number] => 20210060124
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-04
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/098970
[patent_app_country] => US
[patent_app_date] => 2020-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27769
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 220
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17098970
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/098970 | Methods and compositions for treating Huntington's Disease | Nov 15, 2020 | Issued |